Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Dravet syndrome is a rare and refractory epileptic encephalopathy, and Stiripentol is widely used to improve the seizure status of patients by inhibiting the hepatocytochrome P450 ···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：316
Stiripentol is an innovative antiepileptic drug used to treat Dravet syndrome, mainly by enhancing GABAergic nerve conduction and reducing the frequency of seizures in patients. In···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：287
Fidaxomicin is a white to off-white film-coated oblong tablet and should be used as directed by a healthcare practitioner.How much do the different versions of Fidaxomicin cost?Pri···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：313
Fidaxomicin works by inhibiting the RNA polymerase of bacteria, which has little damage to normal intestinal colonies and is highly safe.How many versions of Fidaxomicin are there?···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：343
Fidaxomicin is a macrolide antibiotic developed by Optimer and approved by the FDA in 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD).What is Fidaxomicin···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：411
Balversa is specifically designed for patients with advanced urothelial carcinoma, targeting patients with FGFR mutations and bringing new hope to patients by inhibiting cancer cel···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：308
Balversa is a targeted drug targeting FGFR mutations for the treatment of advanced urothelial carcinoma, inhibiting cancer cell growth by inhibiting the FGFR signaling pathway, pro···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：386
Balversais an oral anti-tumor drug for the treatment of urothelial carcinoma with FGFR2/3 mutations, which blocks tumor growth by inhibiting FGFR activity, but it is necessary to p···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：297
Balversa is a new anti-cancer drug targeting FGFR, targeting urothelial carcinoma with specific gene mutations, accurately blocking tumor growth signals, and bringing new hope to p···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：335
Balversais an oral anti-cancer drug mainly used for the treatment of advanced or metastatic urothelial carcinoma with FGFR2/3 mutations, which shows anti-tumor potential by inhibit···【more】
Article source：Captain MedicineRelease date：2024-08-28Recommended：413
Balversais an anti-tumor drug for FGFR mutant tumors, which is usually administered orally in clinical practice and has excellent tumor inhibition ability.What are the precautions ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：341
Balversa is an innovative targeted therapy drug that is clinically used in patients with FGFR mutations such as urothelial carcinoma and has a significant antitumor effect through ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：319
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4452025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6312024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：872026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4142025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4312025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4172025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
